Pygeum Africanum and Benign Prostatic Hyperplasia (BPH)

Effectiveness in Treating LUTS: Pygeum africanum, a phytotherapeutic agent, was shown to significantly improve lower urinary tract symptoms (LUTS) in approximately 43% of patients with benign prostatic hyperplasia (BPH), as compared to higher improvement rates in patients taking finasteride (57%) and alpha-blockers (68%).

Clinical Trials and Research Challenges: The use of Pygeum africanum extract in BPH treatment is supported by some short-term clinical efficacy; however, challenges remain due to high placebo responses and limited trial durations. There is a call for large-scale clinical trials to fully evaluate its effectiveness.

Conservation Concerns: Pygeum africanum is sourced from the African cherry tree, which is endangered due to unsustainable harvesting practices. Conservation efforts and alternative cultivation methods are being explored to meet future market demands while protecting the species.

Anti-inflammatory and Antiandrogenic Properties: Research has identified the anti-inflammatory effects of Pygeum africanum extract, particularly its inhibition of leukotriene synthesis, which may contribute to its therapeutic effects in BPH. Compounds like N-butylbenzenesulfonamide (NBBS) and atraric acid isolated from the plant have shown potent antiandrogenic effects, indicating potential for developing new BPH and prostate cancer treatments.

Chemical and Genetic Diversity: Studies on the bioactive compounds in Prunus africana bark have exhibited significant chemical and genetic diversity, emphasizing the importance of sustainable use and conservation strategies for the tree species.

Fatty Acid Analysis: The differentiation of plant species based on fatty acid content through gas chromatography methods helps in product standardization of phytotherapeutic agents like Pygeum africanum.

Antioxidant, Antimicrobial, and Antiproliferative Effects: Various extracts of Prunus africana have demonstrated antioxidant, antimicrobial, and antiproliferative properties, further supporting the therapeutic potential of Pygeum africanum in BPH treatment.

Therapeutic Potential: Pygeum africanum has shown efficacy in improving BPH symptoms and is considered to have benefits over placebo, with a recommendation for further research to establish long-term effectiveness.

Conclusion

Pygeum africanum extract offers promising therapeutic benefits for treating BPH symptoms and has anti-inflammatory and antiandrogenic properties that may be harnessed for prostate health. However, further research is needed to confirm its efficacy and establish sustainable harvesting practices to protect the endangered species.

References:

1. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries
2. A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment of LUTS
3. The African cherry (Prunus africana): can lessons be learned from an over-exploited medicinal tree?
4. African plum and benign prostatic hypertrophy
5. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells
6. Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity
7. Activity-guided isolation of an antiandrogenic compound of Pygeum africanum
8. Bioactive constituents in Prunus africana: geographical variation throughout Africa and associations with environmental and genetic parameters
9. Determination of the Fatty Acid content of pumpkin seed, pygeum, and saw palmetto
10. Identification of components of Prunus africana extract that inhibit lipid peroxidation
11. New constituents of Prunus africana bark extract
12. Inhibition of 5 α-reductase and aromatase by PHL-00801 (Prostatonin®), a combination of PY102 (Pygeum africanum) and UR102 (Urtica dioica) extracts
13. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo
14. The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth
15. NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth
16. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
17. The so-called phyto-estrogenic action of Pygeum africanum extract
18. The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth
19. Chemical constituents, anti-inflammatory and antioxidant activities of bark extracts from Prunus tucumanensis Lillo
20. Pygeum africanum extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts
21. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts
22. Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH)
23. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures
24. Pygeum africanum for benign prostatic hyperplasia
25. Review: Pygeum africanum extracts improve symptoms and urodynamics in symptomatic benign prostatic hyperplasia
26. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis
27. Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial
28. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses
29. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe
30. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension
31. Diabetic cystopathy
32. Pygeum africanum: effect on oxidative stress in early diabetes-induced bladder
33. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model